SPARC and colorectal carcinoma: In summary, we firstly confirmed that the expression of hsa-miR-29c-3p was lower in CRC, inhibited cell migration and proliferation, by targeting SPARC, which revealed a critical role and appeared to be a promising therapeutic target.